Advocacy

Advocacy in Action

May 12, 2022

Transgender Update in the UK and US  

Last summer, we joined LGBTQ+ youth and reproductive health organizations to intervene in the UK case Bell v. Tavistock. We provided the UK Court of Appeal with information about the standard of transgender healthcare, our clinical practice guidelines, and consent of minors.

The Court ruled in our favor, allowing minors with gender dysphoria to provide consent to puberty delaying medication. However, shortly after the ruling, the opposition submitted a request to appeal the decision. We were pleased to learn this week that the Supreme Court in the UK refused permission to appeal the Court of Appeal judgment in this case, citing that the application did not “raise an arguable point of law.” 

In the US, we joined another amicus brief in response to a recently passed law in Alabama that bans gender affirming care. The ban, which is the strictest we have seen, makes it a crime punishable by up to 10 years in prison to provide puberty delaying medicine, hormones, and any medical procedures for transgender and gender diverse youth under 19. The court accepted our amicus brief, but the federal judge presiding over this case did not decide on the matter after the hearing for a temporary restraining order concluded last Friday afternoon. Consequently, the felony ban on gender-affirming care went into effect early Sunday morning. 

We are continuing to monitor the progression of this case as it moves through the court system and continue to stand by our members providing gender affirming care to their patients.

LHHS Appropriators Discuss NIH Budget and Research Priorities

On May 11, the Labor, Health and Human Services and Related Agencies (LHHS) Subcommittee of the House Appropriations Committee conducted a hearing to discuss the Fiscal Year 2023 budget request for the National Institutes of Health (NIH). During their opening remarks, Chairwoman Rosa DeLauro (D-CT) and Ranking Member Tom Cole (R-OK) both celebrated the work of the Subcommittee to secure sustained, bipartisan annual investments that increased funding for NIH by $15 billion over the past 7 years. Representative DeLauro was personally enthusiastic about increased funding for the Office of Research on Women’s Health (ORWH) and was encouraged by NIH’s commitment to reduce health disparities. During the hearing, Subcommittee members posed questions to a small group of selected Institute directors about several issues that were synergistic with the Endocrine Society’s priorities, including: future research needs to address Covid-19, optimizing evidence-based resources for patients, addressing diversity, equity, and inclusion within the biomedical research workforce, and supporting early career researchers. Many members expressed concern about the Biden Administration’s substantial proposed increase for the Advanced Research Projects Agency for Health (ARPA-H) relative to the rest of NIH, and they also worried about the missed opportunities for basic research that would result if ARPA-H competed for funds with other NIH Institutes and Centers. The Endocrine Society will continue to advocate for a substantial increase to the NIH base budget for at least $50 billion in FY2023 and work to ensure that funds for ARPA-H complement, rather than supplant, necessary investments in investigator-initiated research.

Recent Policy Communications 

Last Updated:
Take Action

Make Your Voice Heard

Take Action
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.